GFC Life Science

지에프씨생명과학 · 388610

Materials Chemicals · KOSDAQ

Small-cap

Market cap US$24.9M (₩34.3B)

Overview

GFC Life Science develops specialty ingredients for cosmetics, including active compounds derived from skin microbiome research and exosome extraction technology, and supplies them to domestic and international cosmetics brands.

It also runs a clinical-testing division that provides efficacy and claims-substantiation testing services to cosmetics manufacturers and marketers, a service required under Korean cosmetics regulations. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business lines: materials supply and clinical services.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$12.8M
▲ +5.4% YoY
Operating profit · FY2025
US$279.9K
▼ −77.3% YoY
Net income · FY2025
US$402.5K
Turned profitable

Revenue

  • FY2024US$12.2M
  • FY2025US$12.8M

Operating profit

  • FY2024US$1.2M
  • FY2025US$279.9K

Net income

  • FY2024−US$4.3M
  • FY2025US$402.5K

Key ratios (FY2025)

ROE
2.3%
Debt/Eq
42.2%
Op. margin
2.2%
Net margin
3.1%
Rev. YoY
▲ +5.4%

Why it matters

Korean cosmetics law requires brands to hold certified test data before making efficacy claims in advertising, which underpins the demand for GFC's clinical-testing division.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.